Sunday, November 9, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Sasol Shares Face Analyst Scrutiny Amid Cash Flow Concerns

Robert Sasse by Robert Sasse
September 24, 2025
in Analysis, Chemicals, Energy & Oil
0
Sasol Stock
0
SHARES
76
VIEWS
Share on FacebookShare on Twitter

Morgan Stanley has issued a significant downgrade for South African energy and chemicals group Sasol, shifting its investment stance and lowering the price target. The bank’s revised assessment points to persistent cash flow challenges and deep-seated structural issues within the company’s domestic operations as primary causes for concern.

Revised Rating and Price Target

In a move that underscores growing apprehension, Morgan Stanley adjusted its rating for Sasol from “Overweight” to “Equal-weight” this past Monday. Concurrently, the firm slashed its price target significantly, from 140 South African Rand to 120 Rand. The analysts justified this decision by highlighting disappointing projections for free cash flow in 2026 and 2027, which are anticipated to be a mere 5 to 6 Rand per share. This level of cash generation would imply a valuation multiple of approximately twenty times earnings.

The financial institution’s report suggests that one-off, short-term factors are currently masking the underlying weakness in Sasol’s fundamental ability to generate cash. It noted that debt repayments scheduled for the 2025 fiscal year are largely dependent on a payment from Transnet, fluctuations in working capital, and dividend receipts—all of which are considered temporary sources of funds.

Operational Headwinds and Strategic Challenges

The company is confronting a complex array of operational pressures. Softer global oil and chemical markets are squeezing profit margins, while a stronger South African Rand is increasing the cost of its exports. However, the most significant threats are structural.

Securing a reliable and affordable supply of key raw materials has become a critical vulnerability. Natural gas production in Mozambique is declining, and replacement coal is becoming both more expensive and scarce. Compounding this, Sasol’s own coal production volumes are experiencing a structural downturn. The profitability of its operations is further pressured by rising carbon taxes within South Africa.

Morgan Stanley expresses skepticism regarding Sasol’s ability to successfully navigate these structural challenges. Reflecting this view, the bank reduced its earnings forecasts for 2026 and 2027 by nearly one-fifth. This downward revision is attributed to expectations of lower coal and chemical output, combined with adverse currency effects.

Should investors sell immediately? Or is it worth buying Sasol?

A Glimmer of Hope in Recent Financials

Despite the cautious forward outlook, Sasol demonstrated a notable financial turnaround in its most recent fiscal year, which concluded on June 30, 2025. The company swung from a substantial net loss of 44.3 billion Rand to a net profit of 6.8 billion Rand. This performance fueled a share price recovery of approximately 39% over the year, effectively halting a three-year downward trend.

Key Financial Metrics for Fiscal Year 2025:
* Net Profit: 6.8 billion Rand (a reversal from a loss of 44.3 billion Rand)
* Earnings Per Share: 10.60 Rand (compared to a loss of 69.94 Rand)
* Free Cash Flow: Increased by 75% year-over-year
* Net Debt: $3.7 billion (an 11% reduction)

Although debt levels have decreased, net debt remains above the $3 billion threshold that management has identified as a prerequisite for the potential reinstatement of dividend payments. The company’s leadership now targets achieving this goal by the 2027/2028 period.

New Strategic Direction

Under the leadership of CEO Simon Baloyi, Sasol is pursuing a strategic pivot. The new approach emphasizes increased coal usage, a reduced reliance on gas, and a sharpened focus on renewable energy sources. The strategy aims to cut emissions by 30% before 2030 while simultaneously boosting production at the Secunda facility by a minimum of 4.5%.

Progress is already underway, with Sasol having secured 920 megawatts of renewable energy capacity. This is a step toward its ambitious target of 2 gigawatts by 2030. This transition is designed not only to improve the company’s environmental footprint but also to lower its long-term energy costs.

Sasol’s equity now stands at a critical juncture. While recent operational improvements are commendable, the scale of the structural challenges remains substantial. The stock’s ability to sustain its recovery will largely depend on management’s success in mitigating raw material risks and effectively executing its decarbonization strategy.

Ad

Sasol Stock: Buy or Sell?! New Sasol Analysis from November 8 delivers the answer:

The latest Sasol figures speak for themselves: Urgent action needed for Sasol investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 8.

Sasol: Buy or sell? Read more here...

Tags: Sasol
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Alset Stock
Analysis

Alset Shares: Navigating Volatility Between Short-Term Pressure and Long-Term Gains

November 8, 2025
Trinity Biotech Stock
Analysis

Trinity Biotech Shares Face Persistent Downward Pressure

November 8, 2025
I-Mab Stock
Analysis

NovaBridge Biosciences Unveils Promising Clinical Trial Data and Strategic Rebranding

November 8, 2025
Next Post
SQM Stock

Chile's Lithium Sector Poised for Historic State-Led Transformation

Oncology Institute Stock

Oncology Institute Shares Surge on Government Program Success

180 Life Sciences Stock

Ethereum Treasury Firm's Bold Buyback Plan Raises Alarm

Recommended

Faro Stock

Acquisition Finalized: Faro Shareholders Approve AMETEK’s Premium Buyout

4 weeks ago
Finance_ projections

Insider Stock Sales A Cautionary Tale

2 years ago
Fair Isaac Stock

Fair Isaac’s Bold Strategy Shift Rattles Credit Industry

1 month ago
Schwab U.S. Dividend Equity ETF™ Stock

Navigating Market Divergence: The SCHD Dividend Strategy in Focus

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Oruka Therapeutics Secures Major Funding to Advance Clinical Pipeline

Liberty Uranium Shares Plunge Amid Sustained Selling Pressure

Intevac Acquisition Finalized as Seagate Completes Takeover

Can Emergent BioSolutions Stock Maintain Its Upward Trajectory?

Trinity Biotech Shares Face Persistent Downward Pressure

NovaBridge Biosciences Unveils Promising Clinical Trial Data and Strategic Rebranding

Trending

Alset Stock
Analysis

Alset Shares: Navigating Volatility Between Short-Term Pressure and Long-Term Gains

by Dieter Jaworski
November 8, 2025
0

Alset Inc. shares are currently presenting investors with a complex picture, caught between immediate downward pressure and...

Phunware Stock

Can AI Drive a Turnaround for Phunware Stock?

November 8, 2025
Dare Bioscience Stock

Can Dare Bioscience Stock Reverse Its Fortunes?

November 8, 2025
ARCA biopharma Stock

Oruka Therapeutics Secures Major Funding to Advance Clinical Pipeline

November 8, 2025
Liberty Uranium & Metals Stock

Liberty Uranium Shares Plunge Amid Sustained Selling Pressure

November 8, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Alset Shares: Navigating Volatility Between Short-Term Pressure and Long-Term Gains
  • Can AI Drive a Turnaround for Phunware Stock?
  • Can Dare Bioscience Stock Reverse Its Fortunes?

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com